<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899167</url>
  </required_header>
  <id_info>
    <org_study_id>19-008333</org_study_id>
    <nct_id>NCT04899167</nct_id>
  </id_info>
  <brief_title>Noninvasive Evaluation of Renal Allograft Fibrosis by MRI</brief_title>
  <official_title>Noninvasive Evaluation of Renal Allograft Fibrosis by MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate an MRI method to detect renal fibrosis in patients&#xD;
      after kidney transplantation (KT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis underlying this proposal is that qMT reliably detects development of allograft&#xD;
      fibrosis in human subjects after KT. To test this hypothesis, the qMT-derived bound pool&#xD;
      fraction will be correlated with renal fibrosis as per biopsy in 20 patients 4 or 7 years&#xD;
      after living donor KT. The bound pool fraction will also be compared to renal blood flow,&#xD;
      oxygenation, and function, and the ability of qMT to provide consistent assessments of&#xD;
      fibrosis tested at different magnetic field strengths. Two specific aims will test the&#xD;
      hypotheses that: Specific Aim 1: qMT provides reliable and consequential assessment of&#xD;
      fibrosis in human kidney allografts. Specific Aim 2: Renal fibrosis assessed by qMT in human&#xD;
      kidney allografts is reproducible at 1.5 T and 3.0 T.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, unblinded, Parallel, imaging study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The values and correlation of f with IF</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of qMT with tissue fibrosis (trichrome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The correlation of f with renal function attributes and pro-fibrogenic activity</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of qMT with renal oxygenation, GFR, levels of fibrogenic factors.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>4 years after kidney transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 4 years after KT (N=10); 5 with estimated (e) glomerular filtration rate (GFR) ≤35 mL/min/1.73m2, and 5 with estimated (e) glomerular filtration rate (GFR)&gt;35 mL/min/1.73m2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 years after kidney transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 7 years after KT (N=10); 5 patients with eGFR ≤35 mL/min/1.73m2, and 5 with eGFR&gt;35 mL/min/1.73m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI 1.5T and 3.0T</intervention_name>
    <description>Magnetic Resonance Imaging for Renal Fibrosis</description>
    <arm_group_label>4 years after kidney transplantation</arm_group_label>
    <arm_group_label>7 years after kidney transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  Recipient of living donor kidney transplantation 4 or 7 years earlier&#xD;
&#xD;
          -  Competent and able to provide written informed consent; Ability to comply with&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have clinically significant medical conditions within the prior 6 months&#xD;
             before: e.g. myocardial infarction, congestive heart failure, stroke, that would, in&#xD;
             the opinion of the investigators, compromise the safety of the patient.&#xD;
&#xD;
          -  Severe chronic liver, heart or lung disease&#xD;
&#xD;
          -  Undergoing acute rejection&#xD;
&#xD;
          -  Contra-indication to biopsy; bleeding disorders&#xD;
&#xD;
          -  Chronic infection&#xD;
&#xD;
          -  Any active malignancy and undergoing therapy&#xD;
&#xD;
          -  Kidney or ureteric stone&#xD;
&#xD;
          -  Unable to give valid informed consent&#xD;
&#xD;
          -  Known pregnancy or intent to conceive during the study period&#xD;
&#xD;
          -  Pacemaker, implantable defibrillator, magnetically active metal fragments,&#xD;
             claustrophobia or other contraindication to MRI&#xD;
&#xD;
          -  Federal medical center inmates.&#xD;
&#xD;
          -  Latex allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilach Lerman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Lilach O Lerman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

